Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ZymoGenetics/Serono Will Start Lupus Trials For TACI-Ig In 2nd Half Of 2003

Executive Summary

ZymoGenetics will initiate clinical studies for its autoimmune disease agent TACI-Ig in systemic lupus erythematosis during the second half of 2003, the company said during its Dec. 3 analyst presentation in New York

You may also be interested in...



Serono Broadens Research Pipeline With ZymoGenetics Alliance

Serono will pay over $81 mil. upfront to access ZymoGenetics' therapeutic protein research as part of a broad research, development and commercialization alliance announced Sept. 8

Serono Broadens Research Pipeline With ZymoGenetics Alliance

Serono will pay over $81 mil. upfront to access ZymoGenetics' therapeutic protein research as part of a broad research, development and commercialization alliance announced Sept. 8

Corcept To Test Sluggish IPO Market For Biotechs

Corcept Therapeutics will test the sluggish market for biopharmaceutical initial public offerings with an IPO slated for June 10

UsernamePublicRestriction

Register

PS040926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel